Literature DB >> 22340769

Estrogen-related MxA transcriptional variation in hepatitis C virus-infected patients.

Radwa Y Mekky1, Nabila Hamdi, Wafaa El-Akel, Gamal Esmat, Ahmed I Abdelaziz.   

Abstract

Sex has been reported to influence the rates of viral clearance in hepatitis C virus (HCV)-infected patients. However, little is known regarding the influence of sex on the host genetic response to HCV, which is mediated by the expression of interferon (IFN)-stimulated genes (ISGs) after the activation of janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway by IFN. Thus, we investigated gender differences in MxA genetic profile, which is a downstream reliable marker for JAK/STAT pathway activation. In all, 40 untreated HCV-infected patients were subclassified into premenopausal, postmenopausal, and male patients. The peripheral blood mononuclear cells (PBMCs) from premenopausal women showed the highest MxA gene expression compared to both postmenopausal females and males before and after IFN stimulation. The prestimulation of PBMCs with 17beta-estradiol prior to IFN treatment resulted in a decrease of MxA expression in all groups of patients. That was confirmed by the reversal of this effect using estrogen antagonist ICI182/780. This study demonstrates for the first time the presence of gender variations in the genetic response to chronic HCV infection and to interferon treatment. It also clarifies that estrogen is not the key player in enhancing the JAK/STAT pathway. Copyright Â
© 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22340769     DOI: 10.1016/j.trsl.2011.08.002

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  5 in total

1.  Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS).

Authors:  Elizabeth M Kiefer; Qiuhu Shi; Donald R Hoover; Robert Kaplan; Russell Tracy; Michael Augenbraun; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Mardge Cohen; Elizabeth T Golub; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

2.  Tricistronic hepatitis C virus subgenomic replicon expressing double transgenes.

Authors:  Xin Cheng; Xiang-Cui Gao; Jun-Ping Wang; Xin-Ying Yang; Yan Wang; Bao-Sheng Li; Fu-Biao Kang; Hai-Jun Li; Yue-Min Nan; Dian-Xing Sun
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

3.  17,β-estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle.

Authors:  Andrea Magri; Matteo N Barbaglia; Chiara Z Foglia; Elisa Boccato; Michela E Burlone; Sarah Cole; Paola Giarda; Elena Grossini; Arvind H Patel; Rosalba Minisini; Mario Pirisi
Journal:  Liver Int       Date:  2016-11-25       Impact factor: 5.828

4.  A New Signaling Pathway for HCV Inhibition by Estrogen: GPR30 Activation Leads to Cleavage of Occludin by MMP-9.

Authors:  Laura Ulitzky; Manuel M Lafer; Mark A KuKuruga; Erica Silberstein; Nicoleta Cehan; Deborah R Taylor
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

Review 5.  Sex-Dependent Outcome of Hepatitis B and C Viruses Infections: Synergy of Sex Hormones and Immune Responses?

Authors:  Anna Ruggieri; Maria Cristina Gagliardi; Simona Anticoli
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.